Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease

Deep brain stimulation (DBS) is an established treatment for Parkinson's Disease (PD). Despite the improvement of motor symptoms in most patients by sub-thalamic nucleus (STN) DBS and its widespread use, the neurobiological mechanisms are not completely understood. The objective of the present...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Parkinsonism & related disorders 2019-07, Vol.64, p.235-241
Hauptverfasser: Smith, Gwenn S., Mills, Kelly A., Pontone, Greg M., Anderson, W. Stanley, Perepezko, Kate M., Brasic, James, Zhou, Yun, Brandt, Jason, Butson, Christopher R., Holt, Daniel P., Mathews, William B., Dannals, Robert F., Wong, Dean F., Mari, Zoltan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 241
container_issue
container_start_page 235
container_title Parkinsonism & related disorders
container_volume 64
creator Smith, Gwenn S.
Mills, Kelly A.
Pontone, Greg M.
Anderson, W. Stanley
Perepezko, Kate M.
Brasic, James
Zhou, Yun
Brandt, Jason
Butson, Christopher R.
Holt, Daniel P.
Mathews, William B.
Dannals, Robert F.
Wong, Dean F.
Mari, Zoltan
description Deep brain stimulation (DBS) is an established treatment for Parkinson's Disease (PD). Despite the improvement of motor symptoms in most patients by sub-thalamic nucleus (STN) DBS and its widespread use, the neurobiological mechanisms are not completely understood. The objective of the present study was to elucidate the effects of subthalamic nucleus (STN) DBS in PD on the dopamine system and neural circuitry, employing high-resolution positron emission tomography (PET) imaging. The hypotheses tested were that STN DBS would decrease the striatal vesicular monoamine transporter (VMAT2), secondary to an increase in dopamine concentrations, and would decrease striatal cerebral metabolism and increase cortical cerebral metabolism. PET imaging of the vesicular monoamine transporter (VMAT2) and cerebral glucose metabolism was performed prior to DBS surgery and after 4–6 months of STN stimulation in seven PD patients (mean age 67 ± 7). The patients demonstrated significant improvement in motor and neuropsychiatric symptoms after STN DBS. Decreased VMAT2 was observed in the caudate, putamen and associative striatum and in extra-striatal, cortical and limbic regions. Cerebral glucose metabolism was decreased in striatal sub-regions and increased in temporal and parietal cortices and the cerebellum. Decreased striatal VMAT2 was correlated with decreased striatal and increased cortical and limbic metabolism. Improvement of depressive symptoms was correlated with decreased VMAT2 in striatal and extra-striatal regions and with striatal decreases and cortical increases in metabolism. The present results support further investigation of the role of VMAT2, and associated changes in neural circuitry in the improvement of motor and non-motor symptoms with STN DBS in PD. •Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a treatment for Parkinson's disease.•STN DBS decreased striatal VMAT2 availability, which may reflect increased intra-vesicular dopamine.•STN DBS decreased subcortical and increased posterior cortical metabolism.•Decreased striatal VMAT2 availability was correlated with cortical increases in metabolism, as well as improvement of motor function and depression.•Increased vesicular dopamine and changes in neural circuitry by STN DBS may be associated with motor and non-motor symptom improvement in PD.
doi_str_mv 10.1016/j.parkreldis.2019.04.006
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7304230</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1353802019302019</els_id><sourcerecordid>2229238537</sourcerecordid><originalsourceid>FETCH-LOGICAL-c545t-3ce507565f11e4ed23bf071f9124b987cb748279c4b45dcfd9b6530aa27155883</originalsourceid><addsrcrecordid>eNqFkUtv1TAQhS0Eog_4C8g72CSM7TiPDRItbUGqWqSWteXY4-JLYl_s5Er8-7q6pcCK1Yw0Z84czUcIZVAzYO37Tb3V6UfCyfpcc2BDDU0N0D4jh6zvRCUZb5-XXkhR9cDhgBzlvAGAToJ4SQ4EA1lm7JDYM-fQLDQ6enN7RT-d3NAY6A6zN-ukE51jiHr2AemSdMjbmBZMlFMdLL2bVhMz0hkXPcbJ55n6QL-WZD7kGN5mWuKhzviKvHB6yvj6sR6Tb-dnt6efq8vriy-nHy8rIxu5VMKgLAlb6RjDBi0Xo4OOuYHxZhz6zoxd0_NuMM3YSGucHcZWCtCad0zKvhfH5MPed7uOM1qDoYSe1Db5WadfKmqv_p0E_13dxZ3qBDRcQDF492iQ4s8V86Jmnw1Okw4Y16w45wMXvRRdkfZ7qUkx54Tu6QwD9QBJbdQfSOoBkoJGFUhl9c3fMZ8Wf1MpgpO9AMuzdh6TysZjMGh9KrCUjf7_V-4B1eqpfg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2229238537</pqid></control><display><type>article</type><title>Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Smith, Gwenn S. ; Mills, Kelly A. ; Pontone, Greg M. ; Anderson, W. Stanley ; Perepezko, Kate M. ; Brasic, James ; Zhou, Yun ; Brandt, Jason ; Butson, Christopher R. ; Holt, Daniel P. ; Mathews, William B. ; Dannals, Robert F. ; Wong, Dean F. ; Mari, Zoltan</creator><creatorcontrib>Smith, Gwenn S. ; Mills, Kelly A. ; Pontone, Greg M. ; Anderson, W. Stanley ; Perepezko, Kate M. ; Brasic, James ; Zhou, Yun ; Brandt, Jason ; Butson, Christopher R. ; Holt, Daniel P. ; Mathews, William B. ; Dannals, Robert F. ; Wong, Dean F. ; Mari, Zoltan</creatorcontrib><description>Deep brain stimulation (DBS) is an established treatment for Parkinson's Disease (PD). Despite the improvement of motor symptoms in most patients by sub-thalamic nucleus (STN) DBS and its widespread use, the neurobiological mechanisms are not completely understood. The objective of the present study was to elucidate the effects of subthalamic nucleus (STN) DBS in PD on the dopamine system and neural circuitry, employing high-resolution positron emission tomography (PET) imaging. The hypotheses tested were that STN DBS would decrease the striatal vesicular monoamine transporter (VMAT2), secondary to an increase in dopamine concentrations, and would decrease striatal cerebral metabolism and increase cortical cerebral metabolism. PET imaging of the vesicular monoamine transporter (VMAT2) and cerebral glucose metabolism was performed prior to DBS surgery and after 4–6 months of STN stimulation in seven PD patients (mean age 67 ± 7). The patients demonstrated significant improvement in motor and neuropsychiatric symptoms after STN DBS. Decreased VMAT2 was observed in the caudate, putamen and associative striatum and in extra-striatal, cortical and limbic regions. Cerebral glucose metabolism was decreased in striatal sub-regions and increased in temporal and parietal cortices and the cerebellum. Decreased striatal VMAT2 was correlated with decreased striatal and increased cortical and limbic metabolism. Improvement of depressive symptoms was correlated with decreased VMAT2 in striatal and extra-striatal regions and with striatal decreases and cortical increases in metabolism. The present results support further investigation of the role of VMAT2, and associated changes in neural circuitry in the improvement of motor and non-motor symptoms with STN DBS in PD. •Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a treatment for Parkinson's disease.•STN DBS decreased striatal VMAT2 availability, which may reflect increased intra-vesicular dopamine.•STN DBS decreased subcortical and increased posterior cortical metabolism.•Decreased striatal VMAT2 availability was correlated with cortical increases in metabolism, as well as improvement of motor function and depression.•Increased vesicular dopamine and changes in neural circuitry by STN DBS may be associated with motor and non-motor symptom improvement in PD.</description><identifier>ISSN: 1353-8020</identifier><identifier>EISSN: 1873-5126</identifier><identifier>DOI: 10.1016/j.parkreldis.2019.04.006</identifier><identifier>PMID: 31053531</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Aged ; Brain - diagnostic imaging ; Brain - metabolism ; Cerebral Cortex - diagnostic imaging ; Cerebral Cortex - metabolism ; Corpus Striatum - diagnostic imaging ; Corpus Striatum - metabolism ; Deep Brain Stimulation ; Dopamine ; Female ; Glucose - metabolism ; Humans ; Male ; Middle Aged ; Parkinson Disease - diagnostic imaging ; Parkinson Disease - metabolism ; Parkinson Disease - physiopathology ; Parkinson Disease - therapy ; Parkinson's disease ; Positron emission tomography (PET) ; Positron-Emission Tomography ; Sub-thalamic nucleus ; Subthalamic Nucleus ; Treatment Outcome ; Vesicular Monoamine Transport Proteins - metabolism ; VMAT2</subject><ispartof>Parkinsonism &amp; related disorders, 2019-07, Vol.64, p.235-241</ispartof><rights>2019 Elsevier Ltd</rights><rights>Copyright © 2019 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c545t-3ce507565f11e4ed23bf071f9124b987cb748279c4b45dcfd9b6530aa27155883</citedby><cites>FETCH-LOGICAL-c545t-3ce507565f11e4ed23bf071f9124b987cb748279c4b45dcfd9b6530aa27155883</cites><orcidid>0000-0002-2319-1263 ; 0000-0002-4302-1501 ; 0000-0003-3762-563X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.parkreldis.2019.04.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31053531$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smith, Gwenn S.</creatorcontrib><creatorcontrib>Mills, Kelly A.</creatorcontrib><creatorcontrib>Pontone, Greg M.</creatorcontrib><creatorcontrib>Anderson, W. Stanley</creatorcontrib><creatorcontrib>Perepezko, Kate M.</creatorcontrib><creatorcontrib>Brasic, James</creatorcontrib><creatorcontrib>Zhou, Yun</creatorcontrib><creatorcontrib>Brandt, Jason</creatorcontrib><creatorcontrib>Butson, Christopher R.</creatorcontrib><creatorcontrib>Holt, Daniel P.</creatorcontrib><creatorcontrib>Mathews, William B.</creatorcontrib><creatorcontrib>Dannals, Robert F.</creatorcontrib><creatorcontrib>Wong, Dean F.</creatorcontrib><creatorcontrib>Mari, Zoltan</creatorcontrib><title>Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease</title><title>Parkinsonism &amp; related disorders</title><addtitle>Parkinsonism Relat Disord</addtitle><description>Deep brain stimulation (DBS) is an established treatment for Parkinson's Disease (PD). Despite the improvement of motor symptoms in most patients by sub-thalamic nucleus (STN) DBS and its widespread use, the neurobiological mechanisms are not completely understood. The objective of the present study was to elucidate the effects of subthalamic nucleus (STN) DBS in PD on the dopamine system and neural circuitry, employing high-resolution positron emission tomography (PET) imaging. The hypotheses tested were that STN DBS would decrease the striatal vesicular monoamine transporter (VMAT2), secondary to an increase in dopamine concentrations, and would decrease striatal cerebral metabolism and increase cortical cerebral metabolism. PET imaging of the vesicular monoamine transporter (VMAT2) and cerebral glucose metabolism was performed prior to DBS surgery and after 4–6 months of STN stimulation in seven PD patients (mean age 67 ± 7). The patients demonstrated significant improvement in motor and neuropsychiatric symptoms after STN DBS. Decreased VMAT2 was observed in the caudate, putamen and associative striatum and in extra-striatal, cortical and limbic regions. Cerebral glucose metabolism was decreased in striatal sub-regions and increased in temporal and parietal cortices and the cerebellum. Decreased striatal VMAT2 was correlated with decreased striatal and increased cortical and limbic metabolism. Improvement of depressive symptoms was correlated with decreased VMAT2 in striatal and extra-striatal regions and with striatal decreases and cortical increases in metabolism. The present results support further investigation of the role of VMAT2, and associated changes in neural circuitry in the improvement of motor and non-motor symptoms with STN DBS in PD. •Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a treatment for Parkinson's disease.•STN DBS decreased striatal VMAT2 availability, which may reflect increased intra-vesicular dopamine.•STN DBS decreased subcortical and increased posterior cortical metabolism.•Decreased striatal VMAT2 availability was correlated with cortical increases in metabolism, as well as improvement of motor function and depression.•Increased vesicular dopamine and changes in neural circuitry by STN DBS may be associated with motor and non-motor symptom improvement in PD.</description><subject>Aged</subject><subject>Brain - diagnostic imaging</subject><subject>Brain - metabolism</subject><subject>Cerebral Cortex - diagnostic imaging</subject><subject>Cerebral Cortex - metabolism</subject><subject>Corpus Striatum - diagnostic imaging</subject><subject>Corpus Striatum - metabolism</subject><subject>Deep Brain Stimulation</subject><subject>Dopamine</subject><subject>Female</subject><subject>Glucose - metabolism</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Parkinson Disease - diagnostic imaging</subject><subject>Parkinson Disease - metabolism</subject><subject>Parkinson Disease - physiopathology</subject><subject>Parkinson Disease - therapy</subject><subject>Parkinson's disease</subject><subject>Positron emission tomography (PET)</subject><subject>Positron-Emission Tomography</subject><subject>Sub-thalamic nucleus</subject><subject>Subthalamic Nucleus</subject><subject>Treatment Outcome</subject><subject>Vesicular Monoamine Transport Proteins - metabolism</subject><subject>VMAT2</subject><issn>1353-8020</issn><issn>1873-5126</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtv1TAQhS0Eog_4C8g72CSM7TiPDRItbUGqWqSWteXY4-JLYl_s5Er8-7q6pcCK1Yw0Z84czUcIZVAzYO37Tb3V6UfCyfpcc2BDDU0N0D4jh6zvRCUZb5-XXkhR9cDhgBzlvAGAToJ4SQ4EA1lm7JDYM-fQLDQ6enN7RT-d3NAY6A6zN-ukE51jiHr2AemSdMjbmBZMlFMdLL2bVhMz0hkXPcbJ55n6QL-WZD7kGN5mWuKhzviKvHB6yvj6sR6Tb-dnt6efq8vriy-nHy8rIxu5VMKgLAlb6RjDBi0Xo4OOuYHxZhz6zoxd0_NuMM3YSGucHcZWCtCad0zKvhfH5MPed7uOM1qDoYSe1Db5WadfKmqv_p0E_13dxZ3qBDRcQDF492iQ4s8V86Jmnw1Okw4Y16w45wMXvRRdkfZ7qUkx54Tu6QwD9QBJbdQfSOoBkoJGFUhl9c3fMZ8Wf1MpgpO9AMuzdh6TysZjMGh9KrCUjf7_V-4B1eqpfg</recordid><startdate>20190701</startdate><enddate>20190701</enddate><creator>Smith, Gwenn S.</creator><creator>Mills, Kelly A.</creator><creator>Pontone, Greg M.</creator><creator>Anderson, W. Stanley</creator><creator>Perepezko, Kate M.</creator><creator>Brasic, James</creator><creator>Zhou, Yun</creator><creator>Brandt, Jason</creator><creator>Butson, Christopher R.</creator><creator>Holt, Daniel P.</creator><creator>Mathews, William B.</creator><creator>Dannals, Robert F.</creator><creator>Wong, Dean F.</creator><creator>Mari, Zoltan</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2319-1263</orcidid><orcidid>https://orcid.org/0000-0002-4302-1501</orcidid><orcidid>https://orcid.org/0000-0003-3762-563X</orcidid></search><sort><creationdate>20190701</creationdate><title>Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease</title><author>Smith, Gwenn S. ; Mills, Kelly A. ; Pontone, Greg M. ; Anderson, W. Stanley ; Perepezko, Kate M. ; Brasic, James ; Zhou, Yun ; Brandt, Jason ; Butson, Christopher R. ; Holt, Daniel P. ; Mathews, William B. ; Dannals, Robert F. ; Wong, Dean F. ; Mari, Zoltan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c545t-3ce507565f11e4ed23bf071f9124b987cb748279c4b45dcfd9b6530aa27155883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Brain - diagnostic imaging</topic><topic>Brain - metabolism</topic><topic>Cerebral Cortex - diagnostic imaging</topic><topic>Cerebral Cortex - metabolism</topic><topic>Corpus Striatum - diagnostic imaging</topic><topic>Corpus Striatum - metabolism</topic><topic>Deep Brain Stimulation</topic><topic>Dopamine</topic><topic>Female</topic><topic>Glucose - metabolism</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Parkinson Disease - diagnostic imaging</topic><topic>Parkinson Disease - metabolism</topic><topic>Parkinson Disease - physiopathology</topic><topic>Parkinson Disease - therapy</topic><topic>Parkinson's disease</topic><topic>Positron emission tomography (PET)</topic><topic>Positron-Emission Tomography</topic><topic>Sub-thalamic nucleus</topic><topic>Subthalamic Nucleus</topic><topic>Treatment Outcome</topic><topic>Vesicular Monoamine Transport Proteins - metabolism</topic><topic>VMAT2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smith, Gwenn S.</creatorcontrib><creatorcontrib>Mills, Kelly A.</creatorcontrib><creatorcontrib>Pontone, Greg M.</creatorcontrib><creatorcontrib>Anderson, W. Stanley</creatorcontrib><creatorcontrib>Perepezko, Kate M.</creatorcontrib><creatorcontrib>Brasic, James</creatorcontrib><creatorcontrib>Zhou, Yun</creatorcontrib><creatorcontrib>Brandt, Jason</creatorcontrib><creatorcontrib>Butson, Christopher R.</creatorcontrib><creatorcontrib>Holt, Daniel P.</creatorcontrib><creatorcontrib>Mathews, William B.</creatorcontrib><creatorcontrib>Dannals, Robert F.</creatorcontrib><creatorcontrib>Wong, Dean F.</creatorcontrib><creatorcontrib>Mari, Zoltan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Parkinsonism &amp; related disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smith, Gwenn S.</au><au>Mills, Kelly A.</au><au>Pontone, Greg M.</au><au>Anderson, W. Stanley</au><au>Perepezko, Kate M.</au><au>Brasic, James</au><au>Zhou, Yun</au><au>Brandt, Jason</au><au>Butson, Christopher R.</au><au>Holt, Daniel P.</au><au>Mathews, William B.</au><au>Dannals, Robert F.</au><au>Wong, Dean F.</au><au>Mari, Zoltan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease</atitle><jtitle>Parkinsonism &amp; related disorders</jtitle><addtitle>Parkinsonism Relat Disord</addtitle><date>2019-07-01</date><risdate>2019</risdate><volume>64</volume><spage>235</spage><epage>241</epage><pages>235-241</pages><issn>1353-8020</issn><eissn>1873-5126</eissn><abstract>Deep brain stimulation (DBS) is an established treatment for Parkinson's Disease (PD). Despite the improvement of motor symptoms in most patients by sub-thalamic nucleus (STN) DBS and its widespread use, the neurobiological mechanisms are not completely understood. The objective of the present study was to elucidate the effects of subthalamic nucleus (STN) DBS in PD on the dopamine system and neural circuitry, employing high-resolution positron emission tomography (PET) imaging. The hypotheses tested were that STN DBS would decrease the striatal vesicular monoamine transporter (VMAT2), secondary to an increase in dopamine concentrations, and would decrease striatal cerebral metabolism and increase cortical cerebral metabolism. PET imaging of the vesicular monoamine transporter (VMAT2) and cerebral glucose metabolism was performed prior to DBS surgery and after 4–6 months of STN stimulation in seven PD patients (mean age 67 ± 7). The patients demonstrated significant improvement in motor and neuropsychiatric symptoms after STN DBS. Decreased VMAT2 was observed in the caudate, putamen and associative striatum and in extra-striatal, cortical and limbic regions. Cerebral glucose metabolism was decreased in striatal sub-regions and increased in temporal and parietal cortices and the cerebellum. Decreased striatal VMAT2 was correlated with decreased striatal and increased cortical and limbic metabolism. Improvement of depressive symptoms was correlated with decreased VMAT2 in striatal and extra-striatal regions and with striatal decreases and cortical increases in metabolism. The present results support further investigation of the role of VMAT2, and associated changes in neural circuitry in the improvement of motor and non-motor symptoms with STN DBS in PD. •Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a treatment for Parkinson's disease.•STN DBS decreased striatal VMAT2 availability, which may reflect increased intra-vesicular dopamine.•STN DBS decreased subcortical and increased posterior cortical metabolism.•Decreased striatal VMAT2 availability was correlated with cortical increases in metabolism, as well as improvement of motor function and depression.•Increased vesicular dopamine and changes in neural circuitry by STN DBS may be associated with motor and non-motor symptom improvement in PD.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>31053531</pmid><doi>10.1016/j.parkreldis.2019.04.006</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-2319-1263</orcidid><orcidid>https://orcid.org/0000-0002-4302-1501</orcidid><orcidid>https://orcid.org/0000-0003-3762-563X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1353-8020
ispartof Parkinsonism & related disorders, 2019-07, Vol.64, p.235-241
issn 1353-8020
1873-5126
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7304230
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Aged
Brain - diagnostic imaging
Brain - metabolism
Cerebral Cortex - diagnostic imaging
Cerebral Cortex - metabolism
Corpus Striatum - diagnostic imaging
Corpus Striatum - metabolism
Deep Brain Stimulation
Dopamine
Female
Glucose - metabolism
Humans
Male
Middle Aged
Parkinson Disease - diagnostic imaging
Parkinson Disease - metabolism
Parkinson Disease - physiopathology
Parkinson Disease - therapy
Parkinson's disease
Positron emission tomography (PET)
Positron-Emission Tomography
Sub-thalamic nucleus
Subthalamic Nucleus
Treatment Outcome
Vesicular Monoamine Transport Proteins - metabolism
VMAT2
title Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T01%3A48%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20STN%20DBS%20on%20vesicular%20monoamine%20transporter%202%20and%20glucose%20metabolism%20in%20Parkinson's%20disease&rft.jtitle=Parkinsonism%20&%20related%20disorders&rft.au=Smith,%20Gwenn%20S.&rft.date=2019-07-01&rft.volume=64&rft.spage=235&rft.epage=241&rft.pages=235-241&rft.issn=1353-8020&rft.eissn=1873-5126&rft_id=info:doi/10.1016/j.parkreldis.2019.04.006&rft_dat=%3Cproquest_pubme%3E2229238537%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2229238537&rft_id=info:pmid/31053531&rft_els_id=S1353802019302019&rfr_iscdi=true